In Brief: Hoechst Marion Roussel
Hoechst Marion Roussel: Requests FTC approval to license generic dicyclomine for treatment of irritable bowel syndrome to DuPont Merck subsidiary Endo Labs to fulfill the consent decree Marion Merrell Dow signed with FTC for final approval of its Rugby acquisition in May 1994, FTC announces Oct. 6. Under the consent decree, MMD agreed that within 12 months of the final date of the consent decree it would license dicyclomine formulation and product technology to a third party and contract manufacture of dicyclomine with a third party until it gains FDA approval for its own product ("The Pink Sheet" June 27, 1994, T&G-12). Hoechst's request will be subject to public comment until Nov. 6...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth